- Home
- MGNX vs DSY Comparison
MGNX vs DSY Comparison
Compare MGNX & DSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- DSY
- Stock Information
- Founded
- MGNX 2000
- DSY 2020
- Country
- MGNX United States
- DSY China
- Employees
- MGNX N/A
- DSY N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- DSY
- Sector
- MGNX Health Care
- DSY
- Exchange
- MGNX Nasdaq
- DSY Nasdaq
- Market Cap
- MGNX 87.7M
- DSY 72.0M
- IPO Year
- MGNX 2013
- DSY N/A
- Fundamental
- Price
- MGNX $1.25
- DSY $1.44
- Analyst Decision
- MGNX Hold
- DSY
- Analyst Count
- MGNX 9
- DSY 0
- Target Price
- MGNX $5.33
- DSY N/A
- AVG Volume (30 Days)
- MGNX 2.6M
- DSY 11.8K
- Earning Date
- MGNX 08-05-2025
- DSY 02-10-2025
- Dividend Yield
- MGNX N/A
- DSY N/A
- EPS Growth
- MGNX N/A
- DSY 120.37
- EPS
- MGNX N/A
- DSY 0.01
- Revenue
- MGNX $154,050,000.00
- DSY $7,323,356.00
- Revenue This Year
- MGNX N/A
- DSY N/A
- Revenue Next Year
- MGNX N/A
- DSY N/A
- P/E Ratio
- MGNX N/A
- DSY $117.69
- Revenue Growth
- MGNX 255.31
- DSY 16.37
- 52 Week Low
- MGNX $0.99
- DSY $0.75
- 52 Week High
- MGNX $5.77
- DSY $6.98
- Technical
- Relative Strength Index (RSI)
- MGNX 37.88
- DSY 58.99
- Support Level
- MGNX $1.19
- DSY $1.31
- Resistance Level
- MGNX $1.41
- DSY $1.47
- Average True Range (ATR)
- MGNX 0.12
- DSY 0.06
- MACD
- MGNX -0.03
- DSY 0.02
- Stochastic Oscillator
- MGNX 4.85
- DSY 91.30
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.